Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
VMP vs HDM and VRD Consolidation in Newly Diagnosed Multiple Myeloma
NCT01208766Phase 3Completed
- Sponsor
- HOVON
- Start
- Jan 2011
- Primary completion
- Dec 2020
- Modality
- Small Molecules, Modified Peptides
- Countries
- 16
01
Overview
Phase 3, randomised, open-label trial of bortezomib, melphalan and lenalidomide in multiple myeloma (MM) (4 arms), sponsored by HOVON. Primary endpoint: Progression-Free Survival. Started Jan 2011; status: completed.
02
Drugs
bortezomibmelphalanlenalidomide
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT01208766.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01208766.